Serologic status and safety of inactivated Covid-19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection  

作　　者：Fuchen Liu Xiaochen Feng Jin Du Minghao Ruan Hui Liu 

机构地区：[1]The Third Department of Hepatic Surgery,Eastern Hepatobiliary Surgery Hospital,Third Affiliated Hospital,Second Military Medical University,Naval Medical University,Shanghai,P.R.China

出　　处：《Cancer Communications》2023年第3期409-412,共4页癌症通讯（英文）

基　　金：the Ethics Committee of Eastern Hepatobiliary Surgery Hospital(EHBHKY2022-K-003)。

摘　　要：Dear Editor,Patients with hepatocellular carcinoma(HCC)usually have concomitant chronic liver diseases or cirrhosis,which contribute to a high risk of hepatic decompensation and increasedmortality following the coronavirus disease 2019(Covid-19)infection[1–3].Worldwide,approximately 54%of HCC cases are associated with hepatitis B virus(HBV)infection[1].Cirrhotic patients after curative hepatectomy for HBV-related HCC represent a special group of patients.Although cirrhotic patients have low immunogenicity to Covid-19 vaccination and are recommended to be prioritized for it,the safety and immunogenicity have not been observed in cirrhotic patients with a history of hepatectomy for HCC[2–4].In this study,we explored the immunogenicity and safety after Covid-19 vaccination in patients with liver cirrhosis and a history of hepatectomy for HCC.

关 键 词：PATIENTS CIRRHOSIS HEPATOCELLULAR 

分 类 号：R575.2[医药卫生—消化系统] R735.7[医药卫生—内科学]